Alemtuzumab in Chronic Lymphocytic Leukemia

A clinical practice guideline for adult patients with chronic lymphocytic leukemia (CLL). This guideline examines the use of alemtuzumab, and its associated adverse treatment-related toxicities. Although no definitive data on quality of life or overall survival was identified, case-series studies suggest alemtuzumab could still be a reasonable option for patients with progressive and symptomatic CLL.